ANN ARBOR, MI--(Marketwire - November 14, 2007) - Pipex Pharmaceuticals, Inc. (AMEX: PP) (“Pipex”), a specialty pharmaceutical company developing innovative late-stage drug candidates for the treatment of neurologic and fibrotic diseases, announced clinical results of Alzheimer’s disease test using FreeBound, Pipex’s proprietary pharmacodiagnostic device for measurement of serum free and total copper.
